

EPHMRA
ANATOMICAL CLASSIFICATION
GUIDELINES 2025

Section B

Changed Classes/Guidelines

Final Version

Date of issue: 20th December 2024

A7	INTESTINAL DISORDER PRODUCTS Products for functional gastro-intestinal disorders are in A3 and products for constipation and bowel cleansing are in A6.	r2019
A7A	INTESTINAL ANTI-INFECTIVES Includes all products containing one or more intestinal anti-infectives with or without other substances that are used for diarrhoea and/or hepatic encephalopathy. Sulphonamides and special antibacterials such as polymyxin, neomycin, vancomycin or colistin in oral form, when mainly indicated as antidiarrhoeals are included in this group. Combinations with motility inhibitors, intestinal adsorbents and micro-organisms are also included. Products containing rifaximin for either diarrhoea or hepatic encephalopathy are classified here. Products containing fidaxomicin for <i>Clostridium difficile</i> intestinal infections are classified here.	r2019
A7B	INTESTINAL ADSORBENT ANTIDIARRHOEALS Includes products such as kaolin and pectin. Combinations with micro-organisms are also included.	r2011
A7C	Out of use; can be reused.	
A7D	Out of use; can be reused.	
A7E	INFLAMMATORY BOWEL DISORDER PRODUCTS Includes products for inflammatory bowel disorders. Immunosuppressant products used for inflammatory bowel disorders as well as other conditions are classified in L4, for example in L4B (anti-TNF products).	r2025
A7E1	Intestinal aminosalicylate products Includes products containing balsalazide, mesalazine, olsalazine, sulfasalazine and similar aminosalicylates for inflammatory bowel disorders. Products containing aminosalicylates and indicated for rheumatoid arthritis are classified in MIC.	I2017
A7E2	Intestinal corticosteroid products Includes products containing corticosteroids for inflammatory bowel disorders and for eosinophilic oesophagitis.	r2023

A7E9	<p>Inflammatory bowel disorder products, other</p> <p>Includes other products for inflammatory bowel disorders. Products containing vedolizumab and indicated for inflammatory bowel disease only are classified here.</p> <p>Products containing disodium cromoglicate and indicated for food allergy are classified here.</p> <p>Darvadstrocel (allogenic stem cells) for perianal fistulae in Crohn's disease are classified here.</p> <p>Products containing sphingosine-1-phosphate (S1P) receptor modulators, eg etrasimod, ozanimod etc, for inflammatory bowel disease only, eg ulcerative colitis, Crohn's disease etc, are classified here. Products containing S1P receptor modulators and indicated for both inflammatory bowel disease and multiple sclerosis are classified in N7A.</p>	r2025
A7F	<p>ANTIDIARRHOEAL MICRO-ORGANISMS</p> <p>Includes micro-organisms such as lactobacillus acidophilus which are indicated for the treatment of diarrhoeal disease. Excluded are combinations with other antidiarrhoeals such as anti-infectives, motility inhibitors, and intestinal adsorbents. Products containing racecadotril are classified in A7X.</p>	r2020
A7G	<p>ORAL ELECTROLYTE REPLACERS</p> <p>Oral electrolyte replacers are included in this group where diarrhoeal disease has been indicated. Intravenous preparations are included in K.</p>	I1993
A7H	<p>MOTILITY INHIBITORS</p> <p>Includes narcotic derivatives such as loperamide, diphenoxylate and paregoric. Combinations with intestinal adsorbents and micro-organisms are also included.</p>	I1993
A7X	<p>INTESTINAL DISORDER PRODUCTS, OTHER</p> <p>Includes other products for intestinal disorders, including antidiarrhoeal products. Products containing racecadotril only, or in combination with micro-organisms, are classified here.</p>	r2020

A10X	OTHER DRUGS USED IN DIABETES	R2010
A10X1	Antidiabetic multitherapy combination products	I2010
	Includes combinations of antidiabetics with cardiovascular drugs where the aim is to treat both the diabetes and the cardiovascular condition. For example, rosiglitazone in combination with simvastatin. Also includes combinations of antidiabetics with anti-obesity drugs where the aim is to treat both the diabetes and the obesity. For example, metformin in combination with sibutramine.	
A10X9	Other drugs used in diabetes	r2025
	Includes products used for the treatment of diabetes, as well as adjuvant therapy in the treatment and prevention of conditions associated with or developing from diabetes.	
	Includes aldose reductase inhibitors (eg epalrestat, tolrestat), guar gum and glucose products specifically intended for the treatment of hypoglycaemic shock.	
	Includes products containing glucokinase activator antidiabetics, eg dorzagliatin.	
	Includes products containing glitazars, eg carfloglitazar, saroglitazar etc.	
	Teas and other herbal extracts used as adjuvant therapy are classified here.	
	Products containing teplizumab or cell-based therapies (eg donislecel) for type 1 diabetes, are classified here.	
	Products containing gabapentinoids for diabetic neuropathy are classified in N2D.	

A16	OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS	
A16A	<p>OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS</p> <p>Includes all alimentary tract and metabolism products not classified elsewhere. Oral preparations containing procaine are classified in A13A1.</p> <p>Products containing one or more oral antidiabetic substances in combination with one or more substances from a cardiovascular class where the aim is to treat both the diabetes and the cardiovascular condition are classified in A10X1.</p> <p>Products containing teduglutide for short bowel syndrome are classified here.</p> <p>Products containing prebiotic fibre for gut health and/or immune support are classified here. Products containing prebiotic fibre in combination with probiotic micro-organisms for gut health and/or immune support are classified here.</p> <p>Products containing lumasiran for primary hyperoxaluria type 1 are classified in G4X.</p> <p>Products containing elapegademase or pegademase for severe combined immunodeficiency disease (SCID) associated with a deficiency of adenosine deaminase are classified in L3A9.</p>	r2025

B	BLOOD AND BLOOD FORMING ORGANS	
B1	ANTITHROMBOTIC AGENTS	R1994
B1A	VITAMIN K ANTAGONISTS	R2004
	Includes coumarin and indanedione derivatives.	
B1B	HEPARINS	R2004
B1B1	Unfractionated heparins	
	Includes injectable high molecular weight (unfractionated) heparin (pure and in combination with other substances) with an average molecular weight from 5000 up to 30000 Dalton. The molecules are unfractionated.	
B1B2	Fractionated heparins	R2003
	Includes injectable low molecular weight (fractionated) heparin (pure and in combination with other substances) with an average molecular weight from 2000 up to 18000 Dalton. The molecules are fractionated (fragments). Included are, eg bemiparin, enoxaparin, tedelparin and tinzaparin.	
B1B3	Heparins for flushing	r2025
	Includes heparin products for use with catheters eg Hepflush etc.	
	Catheter lock solution products that contain heparin, eg Heplock etc, are classified here. Catheter lock solution products without heparin are classified in K7A.	
B1B9	Other heparins	R2004
B1C	PLATELET AGGREGATION INHIBITORS	r2017
	Includes all products claiming platelet aggregation inhibition as the main indication eg ticlopidine. Also included are those products which have specific packs or presentations which are mainly indicated for platelet aggregation inhibition. These products, such as sulphinpyrazone, ditazole, dipyridamole, aspirin and non-steroidal anti-inflammatories are also prescribed for other conditions.	
B1C1	Cyclo-oxygenase inhibitor platelet aggregation inhibitors	R2010
	Includes specific presentations of eg acetylsalicylic acid (aspirin), indobufen, picotamide, sulfinpyrazone, which are mainly indicated for platelet aggregation inhibition.	
	All oral solid low-dose aspirin products (162mg and below) are classified in B1C1 worldwide.	

B1X	<p>OTHER ANTITHROMBOTIC AGENTS</p> <p>Includes danaparoid, dermatan sulphate, activated protein C (drotrecogin alpha, activated), fondaparinux, <i>Ligustrum lucidum</i>, pentosan polysulphate sodium, poloxalkol, protein C. Products containing caplacizumab for acquired thrombotic thrombocytopenic purpura (aTTP) are classified here. Products containing apadantase alfa in combination with cinaxadamtase alfa for congenital thrombotic thrombocytopenic purpura (cTTP) are classified here.</p>	r2025
------------	---	-------

B2D	BLOOD COAGULATION PRODUCTS	r2024
	Products used to treat haemophilia are classified in the appropriate fourth level according to the blood factors or blood fractions whose dysfunction they correct, eg by replacement, substitution, gene therapies etc.	
B2D1	Factor VIII, including substitutes	r2024
	Products for haemophilia A containing factors, substitutes or gene therapies, eg valoctogene roxaparvovec, are classified here. Includes antihemophilic globulin A, emcizumab, etc. Products containing von Willebrand factor only are classified in B2D9.	
B2D2	Factors II, VII, IX and X	r2024
	Products for haemophilia B containing factors, substitutes or gene therapies, eg etranacogene dezaparvovec, fidanacogene elaparvovec etc, are classified here. Includes antihemophilic globulin B and prothrombin complex.	
B2D3	Haemophilia anti-inhibitor products	r2025
	Products for haemophilia A and/or haemophilia B, when inhibitors are present or are not present, are classified here. Includes activated FVII (FVIIa), aPCC (activated prothrombin complex concentrate), concizumab, eptacog alfa, marstacimab etc.	
B2D4	Factor XIII	
B2D5	Fibrinogen	
B2D6	Fresh frozen plasma and antihemophilic plasma	
B2D7	Cohn-Fraction I	
B2D8	Platelet concentrates	
B2D9	Blood coagulation products, other	r2025
	Includes products containing von Willebrand factor (single ingredient).	
	Products containing fitusiran for haemophilia are classified here.	
B2E	PLATELET-ENHANCING PRODUCTS	R2023
B2E1	Thrombopoietin agonists	I2023
	Includes products containing thrombopoietin agonists for thrombocytopenia, eg avatrombopag, eltrombopag, hetrombopag olamine, lusutrombopag, romiplostim, thrombopoietin, etc.	

B3	ANTI-ANAEMIC PREPARATIONS	
B3A	HAEMATINICS, IRON AND ALL COMBINATIONS	
	Any products which contain iron, irrespective of other ingredients (for example, folic acid, vitamin B12, etc.) are classified in B3A.	
B3A1	Plain iron	
	This class also includes preparations containing ingredients for better absorption and/or reducing agents, such as ascorbic acid, as well as combinations with cobalt.	
B3A2	Iron combination products	R1993
	Includes all other iron combinations including those containing liver extract and/or folic acid.	
B3B	LIVER EXTRACTS AND COMBINATIONS WITH B12	
	Includes liver extracts, excluding all preparations not used for anaemia. Oral B12 with intrinsic factor allocated is classified in B3B.	
B3C	ERYTHROPOIETIN PRODUCTS	R1995
B3D	HIF-PH INHIBITORS	I2020
	Includes products containing HIF-PH (hypoxia-inducible factor prolyl hydroxylase) inhibitors (for example, daprodustat, enarodustat, molidustat, roxadustat, vadadustat, etc) for the treatment of anaemia in chronic kidney disease.	
B3X	OTHER ANTI-ANAEMIC PRODUCTS, INCLUDING FOLIC ACID, FOLINIC ACID	r2025
	Folinic acid products with more than one indication are classified in V3D.	
	Includes products containing betibeglogene autotemcel for beta thalassaemia, luspatercept for anaemia associated with beta thalassaemia, sutimlimab for inhibition of haemolysis in cold agglutinin disease.	
	Products containing mitapivat for pyruvate kinase deficiency (PKD) are classified here.	
	Products for sickle cell disease (SCD), including those for haemolytic anaemia associated with SCD, eg voxelotor, are classified in B6X.	

B6	ALL OTHER HAEMATOLOGICAL AGENTS	R1996
B6A	Out of use; can be reused from 1999.	D1996
B6B	HYALURONIDASE	
B6C	Out of use	D2020
B6D	HEREDITARY ANGIOEDEMA PRODUCTS	I2015
	Includes products containing eg C1 inhibitor/conestat alfa, ecallantide, icatibant, etc when indicated for hereditary angioedema.	
B6X	OTHER HAEMATOLOGICAL AGENTS	r2025
	Includes haemins. Excluded are those preparations used in the treatment of veins and haemorrhoids (C5) and preparations for dermatological use (D3A).	
	Products containing fostamatinib or oprelvekin for the prevention of severe thrombocytopenia are classified in B2E9.	
	Products containing complement inhibitors: for paroxysmal nocturnal haemoglobinuria (PNH) and/or atypical haemolytic uraemic syndrome (aHUS) only are classified here; for kidney conditions only, eg IgA nephropathy, are classified in G4X; for multiple conditions are classified in L4X.	
	Products for sickle cell disease (SCD), including those for haemolytic anaemia associated with SCD, eg voxelotor, are classified here.	
	Products for haemolysis in cold agglutinin disease, and pyruvate kinase deficiency (PKD) are classified in B3X.	

C2A	ANTIHYPERTENSIVES (OF NON-HERBAL ORIGIN) PLAIN It includes plain antihypertensives and combinations other than those with diuretics, eg combinations of two synthetic antihypertensives or combinations of one synthetic antihypertensive with reserpine.	
C2A1	Antihypertensives plain, mainly centrally acting	
C2A2	Antihypertensives plain, mainly peripherally acting Includes products containing doxazosin. Products containing indoramin alone are classified here unless the indication is migraine in which case they are classified in N2C9.	r2015
C2A3	Antihypertensives plain, others Includes products containing aprocitentan.	r2025
C2B	ANTIHYPERTENSIVES (OF NON-HERBAL ORIGIN), COMBINATION WITH DIURETICS	
C2B1	Antihypertensive-diuretic combinations, mainly centrally acting	
C2B2	Antihypertensive-diuretic combinations, mainly peripherally acting	
C2B3	Antihypertensive-diuretic combinations, others	
C2C	RAUWOLFIA ALKALOIDS AND OTHER ANTIHYPERTENSIVES OF HERBAL ORIGIN	
C2D	RAUWOLFIA ALKALOIDS AND OTHER ANTIHYPERTENSIVES OF HERBAL ORIGIN IN COMBINATION WITH DIURETICS	

C3	DIURETICS	
C3A	DIURETICS	
	Combinations with potassium belong to C3A1, C3A2 or C3A3.	
C3A1	Potassium-sparing agents plain	r2025
	This group includes all products containing amiloride and triamterene, plain.	
	Products containing anticorticosteroids for diuresis, eg eplerenone, spironolactone (canrenoic acid) etc, are classified here.	
C3A2	Loop diuretics plain	r2008
	This group includes all products containing bumetanide, etacrynic acid, etozolin, furosemide, muzolimine, piretanide plain.	
C3A3	Thiazides and analogues plain	r2008
	This group includes all products containing thiazides, eg altizide, bendroflumethiazide, benzyhydrochlorothiazide, butizide, chlorothiazide, cyclopenthiiazide, flumethiazide, hydrochlorothiazide, mebutizide, paraflutizide, teclothiazide, trichlormethiazide and analogues (which act similar to thiazides) eg chlortalidone, clopamide, indapamide, mefruside, tienilic acid, xipamide, tripamide, metolazone, quinethazone, clorexolone and meticrane.	
C3A4	Potassium-sparing agents with loop diuretic combinations	
C3A5	Potassium-sparing agents with thiazides and/or analogue combinations	
C3A6	Out of use; can be reused from 2014.	D2011
C3A7	Vasopressin receptor antagonist diuretics	I2011
	Includes products containing vasopressin receptor antagonists such as conivaptan, mozavaptan and tolvaptan.	
C3A9	Other diuretics	r2021
	Includes eg carboanhydrase inhibitors such as clofenamide and diclofenamide (when not used for the treatment of glaucoma or primary periodic paralysis), diuretics of vegetable origin etc, ethoxazolamide, isosorbide, mannitol, chlorazanyl; mercury salts are also included in this group.	
	Products containing diclofenamide for primary periodic paralysis are classified in M5X. Products containing diclofenamide for glaucoma are classified in S1E1.	

C6	OTHER CARDIOVASCULAR PRODUCTS	R2017
C6A	Out of use; can be reused from 2020.	D2017
C6B	PULMONARY ARTERIAL HYPERTENSION (PAH) PRODUCTS	I2017
C6B1	Endothelin receptor antagonist PAH products Includes products for pulmonary arterial hypertension (PAH) containing endothelin receptor antagonists such as ambrisentan, bosentan, macitentan, sitaxentan, etc.	I2017
C6B2	PDE5 inhibitor PAH products Products containing PDE5 inhibitors and indicated only for pulmonary arterial hypertension (PAH) are classified here. Products containing PDE5 inhibitors and indicated for both erectile dysfunction and PAH are classified in G4E1.	I2017
C6B3	Prostacyclin agonist PAH products Products containing prostacyclin agonists (eg iloprost, selexipag, treprostinil) and indicated for pulmonary hypertension only, are classified here. Products containing epoprostenol are all classified here. Products containing prostacyclin agonists and indicated for platelet aggregation inhibition are classified in B1C4. Products containing prostacyclin agonists for PAH and other conditions are classified in B1C4.	I2017
C6B9	Pulmonary arterial hypertension (PAH) products, other Includes other products for PAH, eg those containing soluble guanylate synthase stimulators such as riociguat. Includes products containing two or more substances from different PAH product classes. For example, an endothelin receptor antagonist in combination with a PDE5 inhibitor.	r2025
C6X	OTHER CARDIOVASCULAR PRODUCTS This group includes all other products that are mainly recommended for diseases of the cardiovascular system and that cannot be classified in groups C1-C6B or C7-11. Potassium and magnesium aspartate are usually classified here. In certain cases when these compounds are indicated as mineral supplements, they are classified in A12. Products containing icatibant for hereditary angioedema are classified in B6D. Products containing SGLT2 inhibitors for diabetes and/or cardiovascular risk are classified in A10P1. Products containing avacopan for vasculitic conditions, eg granulomatosis with	r2025

polyangiitis, microscopic polyangiitis etc, are classified here.

C10	LIPID-REGULATING/ANTI-ATHEROMA PRODUCTS Excludes products intended for weight reduction.	r2025
C10A	LIPID-REGULATING PRODUCTS Includes all products regulating cholesterol and triglycerides. Combinations with products of group C4 should be classified here. Combinations with oral antidiabetic substances are classified in A10X1.	r2025
C10A1	Statins (HMG-CoA reductase inhibitors) Includes atorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin simvastatin. Combinations of statins with ezetimibe are classified in C10C.	R2006
C10A2	Fibrates Includes beclobrate, bezafibrate, ciprofibrate, clofibrate, clofibrade, etofibrate, fenofibrate, gemfibrozil, simfibrate.	I1997
C10A3	Ion-exchange resins Includes cholestyramine, colestipol, polidexide.	I1997
C10A4	PCSK9 inhibitors Includes proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, eg alirocumab, evolocumab.	I2016
C10A9	Lipid-regulating products, other Includes ezetimibe, probucol, tiadenol, pyridinolcarbamate and all other products excluding those in C10B. Combinations of ezetimibe with statins or with bempedoic acid are classified in C10C. Nicotinic acid derivatives if indicated in this area are classified here, eg acipimox. Products containing volanesorsen for familial chylomicronaemia syndrome (FCS) are classified here. Products containing evinacumab for homozygous familial hypercholesterolaemia are classified here.	r2025

D3	WOUND HEALING AGENTS	
D3A	WOUND HEALING AGENTS	R2002
D3A1	Skin/dermal/epidermal/equivalents Includes bioengineered and living human skin equivalents, and also skin growth factors	R2006
D3A9	All other wound healing agents Includes topical preparations for open wounds, ulcers, etc. Wound healing topical vitamins and topical anabolic steroids should be included in this group when they cannot be classified satisfactorily elsewhere. Combinations of enzymes with anti-infectives used for wound healing are classified here. This group also includes skin regeneratives and stimulants, topical extracts, eg of camomile, unspecified suspensions and topical preparations for prophylaxis and therapy of mastitis. Topical oestrogens when used for gynaecological purposes are classified in G2F. Topical haemostyptics including those for dental use are classified here. Antibiotic-containing collagen implants (eg sponges) are classified here. Products containing diperoxochloric acid for the treatment of diabetic foot ulcer are classified here.	r2025

<p>D5</p>	<p>NONSTEROIDAL PRODUCTS FOR INFLAMMATORY SKIN DISORDERS</p> <p>Includes products for psoriasis, hyperkeratosis, ichthyosis, eczema, dermatitis, seborrhoea. Psoralens are classified here when used for inflammatory conditions. Excluded from this class are combinations with antibacterials (D6A), antifungals (D1A) and products specifically indicated in acne (D10A). Sulphur baths which contain other substances besides sulphur and are not used for dermatological purposes, are classified in M2A.</p>	<p>r2019</p>
<p>D5A</p>	<p>TOPICAL ANTIPSORIASIS PRODUCTS</p> <p>Includes products containing substances such as tar, coal tar, ichthammol, dithranol, psoralens, salicylic acid for the treatment of psoriasis. These products may also be for other inflammatory skin conditions. Products containing corticosteroids in combination with coal tar or salicylic acid for psoriasis are classified here. These products may also be for other inflammatory skin conditions.</p> <p>Includes products consisting of coal tar or calcipotriol, alone or in combination, when indicated for psoriasis.</p>	<p>r2019</p>
<p>D5B</p>	<p>SYSTEMIC ANTIPSORIASIS PRODUCTS</p> <p>Includes products for the treatment of psoriasis. These products may also be for other inflammatory skin conditions. Products containing brodalumab, ixekizumab, secukinumab or ustekinumab and indicated for psoriasis and also other non-skin conditions, eg arthritis, are classified in L4C. Psoriatic arthritis is defined as a skin condition.</p> <p>Apremilast is classified here if only for psoriatic skin conditions. Products containing apremilast for multiple conditions are classified in L4X.</p> <p>Products containing deucravacitinib for psoriasis are classified here.</p> <p>Products containing bimekizumab for psoriatic skin conditions only are classified here. Products containing bimekizumab for both skin conditions and non-skin conditions, eg axial spondyloarthritis, ankylosing spondylitis etc, are classified in L4C.</p>	<p>r2025</p>

D10	ANTI-ACNE PREPARATIONS	
D10A	<p>TOPICAL ANTI-ACNE PREPARATIONS</p> <p>Includes all topical dermatological preparations indicated for the treatment of acne or rosacea which may contain corticosteroids, antibacterials, etc.</p> <p>Also includes soaps and shampoos which are specifically indicated for the treatment of acne.</p> <p>Products used to physically remove blackheads, eg adhesive strips etc, are classified in D11A.</p>	r2025
D10B	<p>ORAL ANTI-ACNE PREPARATIONS</p> <p>Includes special hormonal preparations indicated exclusively for the treatment of acne, and also antibacterials and other products indicated for the exclusive treatment of acne. Products that are indicated for both oral contraception and acne are classified in G3A.</p>	r2017

D11	OTHER DERMATOLOGICAL PREPARATIONS	
D11A	<p>OTHER DERMATOLOGICAL PREPARATIONS</p> <p>Includes medicated shampoos, medicated soaps, scalp lotions (other than in D5A, D1A3, D7B, D8A, D10A). Products for pigmentation disorders, androgenetic alopecia, systemic products for the treatment of dermatological conditions, anti-corn agents (plasters, tinctures, including products with salicylic acid especially formulated for warts, corns and calluses etc), products to reduce and improve the appearance of scars, and hair-restorers are classified in this group.</p> <p>Products containing finasteride 1mg and for androgenetic alopecia are classified here. Products containing finasteride 5mg and for BPH are classified in G4C3.</p> <p>Products containing JAK inhibitors, eg ruxolitinib, for atopic dermatitis and/or other inflammatory skin disorders, eg alopecia areata, vitiligo, etc, are classified in D5X.</p> <p>Products containing extracts of chamomile are classified in D3A.</p> <p>Psoralens, when used for inflammatory conditions, are classified in D5.</p> <p>Products containing sirolimus gel for tuberous sclerosis are classified here.</p> <p>Products used to physically remove blackheads, eg adhesive strips etc, are classified here.</p>	r2025

G2	OTHER GYNAECOLOGICALS	
G2A	UTEROTONIC PRODUCTS Includes products used to induce labour (including delivery of placenta) and/or to reduce postpartum haemorrhage. Includes oxytocics and prostaglandins E1 and E2, and products used for cervical dilatation.	r2019
G2B	TOPICAL CONTRACEPTIVES	
G2C	Out of use; can be reused from 2000.	D1997
G2D	PROLACTIN INHIBITORS This group includes products used as prolactin inhibitors and containing bromocriptine, cabergoline, pergolide, quinagolide, terguride etc. Products containing bromocriptine: for multiple conditions are classified here: for diabetes mellitus are only classified in A10X9: for acromegaly only are classified in H1C2: for Parkinson's disease only are classified in N4A. In Japan, all bromocriptine is classified in N4A.	r2025
G2E	LABOUR INHIBITORS This group includes products acting as labour inhibitors eg ritodrine.	I1997
G2F	TOPICAL SEX HORMONES This group includes all topical hormones and/or steroids indicated for gynaecological conditions. Transdermal patches and vaginal formulations containing oestrogens and intended for a systemic effect are classified in G3C. Products containing progesterone in topical form (such as gel) for relief of breast pain are classified here.	r2021
G2X	OTHER GYNAECOLOGICAL PRODUCTS	I1997
G2X1	Gynaecological antispasmodics This group includes oral analgesics and antispasmodics indicated exclusively for dysmenorrhoea.	I1997

G4X	<p>ALL OTHER UROLOGICAL PRODUCTS</p> <p>Includes products containing local anaesthetics used specifically for premature ejaculation.</p> <p>Products for erectile dysfunction are classified in G4E. Products for both erectile dysfunction and other urological conditions are also classified in G4E. Products for improving general sexual performance (not specifically erectile dysfunction) are classified here.</p> <p>Products containing sparsentan for kidney conditions, eg IgA nephropathy, are classified here.</p> <p>Products containing oral budesonide for treatment of IgA nephropathy only are classified here.</p> <p>Products containing complement inhibitors: for kidney conditions only, eg IgA nephropathy, are classified here; for paroxysmal nocturnal haemoglobinuria (PNH) only are classified in B6X; for multiple conditions are classified in L4X.</p> <p>Products containing lumasiran for primary hyperoxaluria type 1 are classified here.</p> <p>Products containing voclosporin for lupus nephritis are classified here.</p>	r2025
------------	---	-------

H2	SYSTEMIC CORTICOSTEROIDS	
H2A	SYSTEMIC CORTICOSTEROIDS, PLAIN	
	Includes all systemic products containing one or more corticosteroid(s) and no other active ingredient, with or without lignocaine.	
H2A1	Injectable corticosteroids, plain	R1993
H2A2	Oral corticosteroids, plain	r2025
	Products containing corticosteroids for eosinophilic oesophagitis are classified in A7E2.	
	Products containing oral budesonide for treatment of IgA nephropathy only are classified in G4X.	
H2A3	Other systemic corticosteroids, plain	r2017
	Includes suppositories. Corticosteroids to treat inflammatory intestinal disorders are classified in A7E2.	
H2B	SYSTEMIC CORTICOSTEROID COMBINATIONS	r2020
	Systemic products containing one or more corticosteroid(s) and one or more other active ingredient(s) (eg antihistamine). Also includes extracts containing natural corticosteroids, but excluding products classified in the following groups:	
	A7E2 – Intestinal anti-inflammatory agents	
	H4X – Liver extracts with small doses of corticosteroids (mainly in Italy).	
	G3X - Gland extracts (mammary, placenta, etc) and corticoid extracts mainly indicated for sexual disorders.	
	G4C7 – Corticosteroids with alpha-adrenergic antagonists.	
	M1B - Corticosteroids with anti-inflammatory agents, analgesics, muscle relaxants, etc.	
	R1B – Systemic nasal preparations	
	R3D, R3F, R3L3 - Anti-asthmatic inhalants acting topically on the bronchioles.	

H4	OTHER HORMONES	
H4A	CALCITONINS	
	This group includes all calcitonin products (pork, salmon, eel and synthetic).	
H4B	GLUCAGON	
H4C	GROWTH HORMONES	r2023
	Includes products for growth conditions and also for AIDS wasting conditions. Products containing anamorelin for cachexia are classified here. Products containing lonapegsomatropin or somatogon are classified here.	
H4D	ANTIDIURETIC HORMONES	
	This group includes argipressin, desmopressin, lypressin, ornipressin, vasopressin.	
H4E	PARATHYROID HORMONES AND ANALOGUES	I2008
	Includes parathyroid hormone analogues, teriparatide.	
H4F	ANTIPARATHYROID PRODUCTS	r2014
	Includes products containing eg cinacalcet, doxercalciferol, falecalcitriol, maxacalcitol, paricalcitol, when they are indicated for secondary hyperparathyroidism. Products containing vitamin D or its analogues with multiple indications are classified in A11C2.	
H4G	ANTICORTICOSTEROID PRODUCTS	I2025
	Products containing anticorticosteroids, eg ketoconazole, levoketoconazole, mifepristone, osilodrostat, trilostane etc for Cushing's syndrome only are classified here.	
	Products containing ketoconazole for other conditions are classified elsewhere.	
	Products containing mifepristone for contraception or gynaecological conditions are classified in G3A6 or G3X.	
	Products containing pasireotide for both Cushing's syndrome and acromegaly are classified in H1C2. Products containing metyrapone for both treatment and diagnosis of Cushing's syndrome are classified in T2X9. Products containing anticorticosteroids for diuresis, for example eplerenone, spironolactone etc, are classified in C3A.	
H4V	Out of use; can be reused from 2011.	D2008
H4X	OTHER HORMONES AND PREPARATIONS WITH SIMILAR ACTIONS	r2009
	Products containing melatonin only and indicated for sleep rhythm disturbances	

are classified here. Prolonged-release melatonin indicated for primary insomnia is classified in N5B1. Products for insomnia that contain a sedative/hypnotic plus melatonin are classified in N5B in the appropriate subclass (N5B2, N5B4 or N5B5).

J1D	CEPHALOSPORINS Includes all systemic cephalosporins, plain or in combination with other anti-infectives, except in combination with tetracyclines (J1A), chloramphenicols (J1B), broad spectrum penicillins (J1C), products in J1K-P, J1X and sulphonamides (J3A). Combinations with phosphonomycin should, however, be included in this class.	R1997
J1D1	Oral cephalosporins Also included are suppository presentations.	
J1D2	Injectable cephalosporins	
J1E	TRIMETHOPRIM AND SIMILAR FORMULATIONS Includes systemic trimethoprim formulations, eg Bactrim/Septin, except in combination with tetracyclines (J1A), chloramphenicols (J1B), broad spectrum penicillins (J1C), cephalosporins (J1D) and products in J1K-P, J1X. Trimethoprim combinations specifically formulated for respiratory infections, eg in combination with expectorants, are classified in R5B.	r2025
J1F	MACROLIDES AND SIMILAR TYPES Includes all systemic macrolides, including erythromycin, spiramycin, oleandomycin, triacetyloleandomycin, kitasamycin, lincomycin and clindamycin, plain or in combination with other anti-infectives, except in combination with tetracyclines (J1A), chloramphenicols (J1B), broad spectrum penicillins (J1C), cephalosporins (J1D), trimethoprim combinations (J1E), products in J1K-P, J1X and sulphonamides (J3A). Also includes streptogramins.	R2003
J1G	FLUOROQUINOLONES This group includes norfloxacin and similar quinolone antibacterials such as fleroxacin, gatifloxacin, grepafloxacin, ofloxacin, pefloxacin and sparfloxacin. Rosoxacin is also included. Excluded are combinations with tetracyclines (J1A), chloramphenicols (J1B), broad spectrum penicillins (J1C), cephalosporins (J1D), trimethoprim formulations (J1E), macrolides (J1F), aminoglycosides (J1K), carbenicillin and similar (J1L), rifampicin/rifamycin (J1M), other beta-lactam antibacterials (J1P), and the miscellaneous antibacterials of J1X. Includes all systemic products containing halogenated quinolones even if only indicated for urinary tract infections. Combinations of halogenated quinolones with other substances and indicated for urinary tract infections are classified in G4A2.	R2009
J1G1	Oral fluoroquinolones Also included are suppository presentations.	r2018
J1G2	Injectable fluoroquinolones	I1997

J3	SYSTEMIC SULPHONAMIDES	
J3A	<p data-bbox="316 248 778 277">SYSTEMIC SULPHONAMIDES</p> <p data-bbox="316 322 1394 461">This group includes plain sulphonamides and sulphonamide/antibacterial combinations but excludes trimethoprim/sulphonamides which are classified in J1E, and specific respiratory formulation, eg in combination with expectorants, which are classified in R5B.</p> <p data-bbox="316 506 1394 719">Sulphonamides indicated primarily as antidiarrhoeals are classified in A7A and those indicated for the treatment of urinary tract infections only are classified in G4A1. In combination products, including other antibacterials, the importance, weight or amount of sulphonamide is unimportant as products containing, say tetracycline, chloramphenicol, oleandomycin and a sulphonamide would be classified in J3A as would a penicillin and three sulphonamides.</p>	r2025

J5	ANTIVIRALS FOR SYSTEMIC USE	R2018
J5A	Out of use	D1998
J5B	ANTIVIRALS, OTHER	r2022
	Includes systemic antivirals for herpes, influenza, coronavirus, other viral respiratory conditions, etc. Excludes topical skin antivirals (D6D), topical ophthalmic antivirals (S1D), HIV antivirals (J5C), and hepatitis antivirals (J5D).	
J5B1	Out of use	D2018
J5B2	Out of use	
J5B3	Herpes antivirals	I2008
	Products used against herpes virus infections, including specific systemic forms of products for cytomegalovirus infections (including CMV retinitis), are classified here. Products in topical ophthalmic forms for CMV retinitis are classified in S1D.	
J5B4	Influenza antivirals	r2025
	Includes products indicated specifically for influenza. Products containing favipiravir for influenza only, or for both influenza and severe fever with thrombocytopenia syndrome (SFTS), are classified here. Products containing favipiravir for COVID-19 only are classified in J5B6. Products containing favipiravir for both influenza and COVID-19 are classified in J5B6.	
J5B5	Respiratory antivirals, other	r2025
	Includes products indicated specifically for treatment of respiratory syncytial virus (RSV) infections. Products containing palivizumab for the prevention of RSV infections are classified in J6H6.	
	Also includes inhalation forms of ribavirin where no indication has been specified.	

J5B6	<p>Coronavirus antivirals</p> <p>Includes products containing bamlanivimab, casirivimab, etesevimab, favipiravir, imdevimab, molnupiravir, sotrovimab, regdanvimab, remdesivir, etc, for treatment of COVID-19.</p> <p>Products containing favipiravir for influenza only are classified in J5B4 (influenza antivirals). Products containing favipiravir for both influenza and COVID-19 are classified here.</p> <p>Products containing immunosuppressants that have been used in COVID-19 are classified elsewhere, for example, levilimab is in L4C. Dexamethasone (has been used in COVID-19) is also classified elsewhere in the appropriate hormone class.</p> <p>Vaccines for coronavirus are classified in J7E6.</p>	r2023
J5B9	<p>Antivirals, others</p> <p>Includes products containing lysozyme for viral infections.</p> <p>Products containing favipiravir for both influenza and severe fever with thrombocytopenia syndrome (SFTS) are classified in J5B4.</p>	r2025

J5D	HEPATITIS ANTIVIRALS	I2018
J5D1	<p>Hepatitis antivirals, interferon and ribavirin</p> <p>Products for hepatitis only containing interferons and/or ribavirin. The products can be for hepatitis B and/or hepatitis C.</p> <p>Products containing interferons and/or ribavirin in combination with a substance from J5D2 are classified in J5D2. Products containing interferons and/or ribavirin in combination with a substance from J5D3 are classified in J5D3. Products containing interferons (with or without ribavirin) that are for multiple indications are classified in L3B.</p>	I2018
J5D2	<p>Hepatitis B antivirals</p> <p>Includes products containing adefovir dipivoxil, clevudine, entecavir, telbivudine, etc.</p> <p>Products containing lamivudine or tenofovir alafenamide for hepatitis B are classified here; products containing lamivudine or tenofovir alafenamide for HIV are classified in J5C1 or J5C8.</p> <p>Combinations of these substances with interferons and/or ribavirin are classified here. Products containing interferons and/or ribavirin for hepatitis B are classified in J5D1.</p> <p>Products containing tenofovir disoproxil only, and indicated for hepatitis, HIV, or for both conditions, are classified in J5C1.</p>	r2025
J5D3	<p>Hepatitis C antivirals</p> <p>Includes products containing asunaprevir, beclabuvir, boceprevir, daclatasvir, dasabuvir, elbasvir, glecaprevir, grazoprevir, ledipasvir, narlaprevir, ombitasvir, paritaprevir, pibrentasvir, simeprevir, sofosbuvir, telaprevir, vaniprevir, velpatasvir, voxilaprevir, etc.</p> <p>Combinations of these substances with each other are also classified here. Combinations of these substances with ritonavir are classified here. Combinations of these substances with interferons and/or ribavirin are classified here. Products containing interferons and/or ribavirin for hepatitis C are classified in J5D1.</p>	I2018
J5D9	<p>Hepatitis antivirals, other</p> <p>Includes other products for viral hepatitis.</p>	I2018

J6E	POLYVALENT IMMUNO-GLOBULINS - INTRAMUSCULAR	R2006
	The action of these homologous substances is based on a wide spectrum of antibodies mainly belonging to the IgG fraction. Includes subcutaneous as well as intramuscular forms.	
J6F	POLYVALENT IMMUNOGLOBULINS - COMBINATION MODULATION - MAINLY INTRAMUSCULAR	
	These homologous immunoglobulins include: - those whose action is not exclusively based on the IgG fraction. - those which exist in combination with other substances. - those which cause a modulation of the immune response.	
J6G	SPECIFIC IMMUNOGLOBULINS - ANTIBACTERIAL	r2022
	These homologous substances (given intramuscularly or intravenously) have a certain antibody titre against a certain specified antigen. Products for post-exposure prophylaxis are classified here. Products for both post-exposure prophylaxis and for treatment are classified here.	
J6G1	Tetanus immunoglobulin	
J6G2	Pertussis immunoglobulin	
J6G9	Other antibacterial immunoglobulins	
	This group includes diphtheria, streptococci, staphylococci and pseudomonas immunoglobulins.	
J6H	SPECIFIC IMMUNOGLOBULINS - ANTIVIRAL	r2025
	These homologous substances (given intramuscularly or intravenously) have a certain antibody titre against a certain specified antigen. Products for prevention/post-exposure prophylaxis are classified here. Products for both prevention/post-exposure prophylaxis and for treatment are classified here. Products for treatment only are classified in J5.	
J6H1	Mumps immunoglobulin	
J6H2	Measles immunoglobulin	
J6H3	Rubella immunoglobulin	
J6H4	Hepatitis immunoglobulin	
J6H5	Rabies immunoglobulin	
J6H6	RSV (respiratory syncytial virus) immunoglobulin	I2025
J6H7	Coronavirus immunoglobulin	I2025

	<p>Monoclonal antibodies for prevention/post-exposure prophylaxis, and for both prevention/post-exposure prophylaxis and treatment of COVID-19 are classified here. Monoclonal antibodies for treatment only of COVID-19 are classified in J5B6.</p>	
--	--	--

<p>J6H9</p>	<p>Other antiviral immunoglobulins</p> <p>This group includes varicella-zoster, tick-borne meningo-encephalitis, poliomyelitis, cytomegaly, and herpes immunoglobulins.</p>	<p>r2025</p>
<p>J6J</p>	<p>OTHER SPECIFIC IMMUNOGLOBULINS</p> <p>These homologous substances (given intramuscularly or intravenously) have a certain antibody titre against a certain specified antigen which is not of bacterial or viral origin.</p> <p>Products containing anti-D (Rho) immunoglobulin are classified here.</p>	<p>r2014</p>

J7E	VIRAL VACCINES	r2018
	Includes separate classes for vaccines against only one viral group. For vaccines against a combination of bacteria or viruses, see J7B.	
J7E1	Influenza vaccines	I2014
J7E2	Varicella vaccines	I2014
J7E3	HPV (human papillomavirus) vaccines	I2014
J7E4	Hepatitis vaccines	I2014
J7E5	Rotavirus vaccines	I2014
J7E6	Coronavirus vaccines	I2021
	Includes vaccines against COVID-19.	
J7E7	RSV (respiratory syncytial virus) vaccines	I2025
J7E9	All other viral vaccines	r2025
	Includes all other vaccines against one viral group, eg Japanese encephalitis, measles, mumps, polio, rubella, rabies, smallpox, tick-borne encephalitis, yellow fever etc.	
J7F	PROTOZOAL VACCINES	I2018
	Includes separate classes for vaccines against only one protozoal group. For vaccines against a combination of a protozoal group and/or other organisms, see J7B.	
J7F1	Malaria vaccines	I2018
J7F9	All other protozoal vaccines	I2018
J7X	ALL OTHER VACCINE-LIKE PRODUCTS	r2018
	Includes products containing infectious agents and/or their derivatives, eg lysates and extracts of bacteria, that are not strictly considered vaccines.	

K1C1	<p>Solutions with one carbohydrate (>10%)</p> <p>The types of products contained in this sub-group are sugar solutions (>10%) such as glucose (dextrose, grape sugar) and fructose (laevulose, fruit sugar). Also included are polyalcohols such as xylitol and sorbitol.</p> <p>Carbohydrate solutions (<=10%) are classified in K1B3.</p>	
K1C2	<p>Carbohydrate combination solutions (>10%)</p> <p>Includes only combinations of two or more carbohydrates eg fructose, glucose, xylitol (FGX) and invert sugar solutions (>10%).</p> <p>Carbohydrate combination solutions (<=10%) are classified in K1B3.</p>	
K1C3	<p>Carbohydrate electrolyte combination solutions (>10%)</p> <p>The group includes single or combined carbohydrates (>10%) eg glucose, fructose, sorbitol and xylitol with electrolytes.</p> <p>The group excludes carbohydrate solutions (single or combined) with electrolytes (carbohydrates <=10%) which are classified in K1A.</p>	
K1D	<p>FAT EMULSIONS, INCLUDING TOTAL PARENTERAL NUTRITION PRODUCTS</p>	R1997
K1D1	<p>Fat emulsions, plain</p> <p>This group includes plain fat emulsions for parenteral applications eg fractions of soybean oil and safflower oil, or mixtures of different oils.</p>	I1997
K1D2	<p>Fat emulsions, combinations</p> <p>This group includes fat emulsions with other substances such as amino acids, glucose, electrolytes. In particular, products for total parenteral nutrition are classified in this class. Multicomponent solutions for total parenteral nutrition with no fat emulsion content, are classified in K1E.</p>	R2006
K1E	<p>AMINO ACID SOLUTIONS</p> <p>This group contains all amino-acid solutions including combinations, except those including fats.</p>	R2006
K1E1	<p>Amino acid standard solutions</p> <p>Includes solutions containing at least all the following amino acids: isoleucine, leucine, lycine, methionine, phenylalanine, threonine, tryptophan, and valine. Products may additionally contain histidine, other non-essential amino-acids, electrolytes, etc.</p>	r2025

<p>K7</p>	<p>PERFUSION SOLUTIONS</p> <p>Perfusion solutions are not to be given intravenously or to be injected. This group includes all solutions which are used for the storage of donor organs and gravity perfusion. Also included are anticoagulant solutions for blood samples. Also products used to arrest the heart are classified here.</p>	<p>R2006</p>
<p>K7A</p>	<p>PERFUSION SOLUTIONS</p> <p>Catheter lock solution products without heparin are classified here. Catheter lock solution products that contain heparin are classified in B1B3.</p>	<p>r2025</p>

L1G	<p>MONOCLONAL ANTIBODY ANTINEOPLASTICS</p> <p>Antineoplastic monoclonal antibodies against protein kinases are classified here and not in L1H.</p> <p>Products containing antibody drug conjugates (ADCs) are classified in the appropriate fourth level, according to the antibody target. If there is not a class for the target, the product is classified in L1G9.</p> <p>Products containing bispecific antibodies are classified in the appropriate fourth level, where a target class is available. If there is not a class for either target, the product is classified in L1G9. If there is a separate class for each target, the product is classified in L1G9.</p>	r2024
L1G1	<p>Monoclonal antibody antineoplastics, CD20</p> <p>Includes products containing obinutuzumab, ofatumumab, rituximab, rituximab with hyaluronidase, etc. Products containing ofatumumab for multiple sclerosis only are classified in N7A.</p>	r2022
L1G2	<p>Monoclonal antibody antineoplastics, VEGF/VEGFR</p> <p>Includes products containing bevacizumab, ramucirumab, etc.</p>	I2019
L1G3	<p>Monoclonal antibody antineoplastics, HER-2</p> <p>Includes products containing margetuximab, pertuzumab, trastuzumab, trastuzumab deruxtecan, trastuzumab emtansine, etc.</p>	r2021
L1G4	<p>Monoclonal antibody antineoplastics, EGFR</p> <p>Includes products containing cetuximab, necitumumab, nimotuzumab, panitumumab, etc.</p>	I2019
L1G5	<p>Monoclonal antibody antineoplastics, PD-1/PD-L1</p> <p>Includes products containing atezolizumab, avelumab, cemiplimab, durvalumab, nivolumab, pembrolizumab, tislelizumab, etc. Products containing a combination of nurulimab with prolgolimab are classified here. Products containing a combination of nivolumab with relatlimab are classified in L1G9. Products containing PD-1/CTLA-4 bispecific antibody antineoplastics, eg cadonilimab, are classified here.</p>	r2025

L1G9	<p>Monoclonal antibody antineoplastics, other</p> <p>Includes antibodies with other targets including other CD targets, CTLA-4 (ipilimumab), etc. Products containing PD-1/CTLA-4 bispecific antibody antineoplastics, eg cadonilimab, are classified in L1G5. Products containing bispecific antibodies are classified in the appropriate fourth level, where a target class is available. If there is not a class for either target, the product is classified here. If there is a separate class for each target, the product is classified here.</p> <p>Includes antibody drug conjugates (ADCs) if not classified with the target class (brentuximab vedotin, gemtuzumab ozogamicin, inotuzumab ozogamicin). Includes radio-labelled antibodies (ibritumomab tiuxetan, tositumomab iodine-131).</p> <p>Includes alemtuzumab, blinatumomab, brentuximab vedotin, catumaxomab, daratumumab, dinutuximab, elotuzumab, gemtuzumab ozogamicin, ibritumomab tiuxetan, inotuzumab ozogamicin, ipilimumab, mogamulizumab, olaratumab, racotumomab, rovalpituzumab tesirine, sabatolimab, siltuximab, tositumomab, tositumomab iodine-131, etc.</p> <p>Includes products containing a combination of nivolumab with relatlimab. Products containing nivolumab alone are classified in L1G5. Products containing a combination of nurulimab with prolgolimab are classified in L1G5.</p> <p>Products containing alemtuzumab and indicated for cancer only are classified here. Products containing alemtuzumab and indicated for multiple sclerosis are classified in N7A.</p>	r2025
L1H	<p>PROTEIN KINASE INHIBITOR ANTINEOPLASTICS</p> <p>Antineoplastic monoclonal antibodies against protein kinases are classified in L1G.</p>	R2019
L1H1	<p>Protein kinase inhibitor antineoplastics, BCR-ABL</p> <p>Includes products containing bosutinib, dasatinib, imatinib, nilotinib, ponatinib, radotinib, etc.</p>	I2019
L1H2	<p>Protein kinase inhibitor antineoplastics, EGFR</p> <p>Includes products containing afatinib, dacomitinib, erlotinib, gefitinib, icotinib, olmutinib, osimertinib, varlitinib, etc.</p>	I2019
L1H3	<p>Protein kinase inhibitor antineoplastics, ALK</p> <p>Includes products containing alectinib, brigatinib, ceritinib, crizotinib, lorlatinib, etc.</p>	I2019



L1H4	<p>Protein kinase inhibitor antineoplastics, BRAF/MEK</p> <p>Includes products containing binimetinib, cobimetinib, dabrafenib, encorafenib, selumetinib, trametinib, vemurafenib, etc.</p>	I2019
L1H5	<p>Protein kinase inhibitor antineoplastics, CDK 4/6</p> <p>Includes products containing abemaciclib, palbociclib, ribociclib, etc. Products containing both ribociclib and letrozole are classified here.</p>	I2019
L1H6	<p>Protein kinase inhibitor antineoplastics, BTK</p> <p>Includes products containing acalabrutinib, ibrutinib, tirabrutinib, zanubrutinib, etc.</p>	I2021
L1H7	<p>Protein kinase inhibitor antineoplastics, JAK</p> <p>Includes products containing fedratinib, momelotinib, pacritinib, ruxolitinib, etc that are primarily for cancer.</p> <p>Products containing JAK inhibitors are classified in A7 if only for gastro-intestinal conditions, in D5 if only for skin conditions (eg topical forms of ruxolitinib for atopic dermatitis), and in M1 if only for musculoskeletal conditions.</p> <p>Products containing JAK inhibitors to treat multiple immune conditions are classified in L4D.</p>	I2024
L1H9	<p>Protein kinase inhibitor antineoplastics, other</p> <p>Includes all other protein kinase inhibitor antineoplastics, for example those inhibiting HER-2 etc. Pi3K inhibitors are included even though they are lipid kinase inhibitors and not strictly protein kinase inhibitors.</p> <p>Includes axitinib, cabozantinib, erdafitinib, everolimus, idelalisib, lapatinib, lenvatinib, midostaurin, neratinib, nintedanib, pazopanib, regorafenib, rivoceranib (apatinib), sorafenib, sunitinib, temsirolimus, tivozanib, vandetanib, etc.</p> <p>Products containing multi-kinase inhibitors, eg umbralisib etc, are classified here.</p> <p>Products containing nintedanib for idiopathic pulmonary fibrosis only are classified in R7D. Products containing nintedanib for cancer only are classified here. Products containing nintedanib for both cancer and idiopathic pulmonary fibrosis are classified in R7D.</p> <p>Products containing alpelisib for PIK3CA-related overgrowth spectrum (PROS) are classified here.</p> <p>Products containing KRAS inhibitors, eg adagrasib, sotorasib, etc, for cancer are</p>	r2025

	classified in L1X9.	
--	---------------------	--

L1X8	<p>Photosensitisers for cancer therapy</p> <p>Includes products containing photosensitisers for use in cancer therapy, eg aminolaevulinic acid, methyl aminolaevulinate, methoxsalen, porfimer, talaporfin, temoporfin, etc.</p> <p>Products containing aminolaevulinic acid for actinic keratosis, basal cell carcinoma or Bowen syndrome are classified here. Products containing aminolaevulinic acid for use in diagnostic procedures are classified in T1X.</p> <p>Products containing methoxsalen for other skin conditions such as psoriasis or vitiligo are classified in the appropriate D classes.</p> <p>Products containing verteporfin for macular degeneration are classified in S1P.</p>	r2023
L1X9	<p>All other antineoplastics</p> <p>Includes amsacrine, enzymes, estramustine, gallium nitrate, methylhydralazine, mitotane, pentostatin, procarbazine, substituted urea, tasonermin, vosaroxin. Also includes celecoxib for familial adenomatous polyposis (FAP).</p> <p>Includes products containing cancer gene therapies eg nadofaragene firadenovec, talimogene laherparepvec, etc.</p> <p>Products containing aflibercept for cancer are classified here. Products containing aflibercept for macular degeneration are classified in S1P.</p> <p>Products containing BCG vaccine for cancer are classified here; those for general immunostimulation are classified in L3A9. Products containing BCG vaccine for active immunisation against tuberculosis are classified in J7D6.</p> <p>Products containing miltefosine for skin metastases of breast cancer are classified here. Products containing miltefosine for leishmaniasis are classified in P1G.</p> <p>Products containing interferons, eg ropeginterferon alfa 2b, for cancer only are classified here.</p> <p>Products containing tabelecleucel for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+PTLD) are classified here.</p> <p>Products containing antineoplastic, non-transformed cell therapies, eg lifileucel, are classified here.</p> <p>Products containing KRAS inhibitors, eg adagrasib, sotorasib, etc, for cancer are classified here.</p>	r2025

L3	IMMUNOSTIMULATING AGENTS	I1994
L3A	IMMUNOSTIMULATING AGENTS EXCLUDING INTERFERONS	R2004
L3A1	<p>Colony-stimulating factors</p> <p>Includes aneastim, empegfilgrastim, filgrastim, lenograstim, molgramostim, pegfilgrastim, sargramostim.</p> <p>Products containing inhaled sargramostim for autoimmune pulmonary alveolar proteinosis (aPAP) are classified in R7X.</p>	r2025
L3A9	<p>All other immunostimulating agents excluding interferons</p> <p>Includes cridanimod, glatiramer acetate, interleukin-2, picibanil.</p> <p><i>Corynebacterium parvum</i> and levamisole are classified here when used as immunostimulants.</p> <p>Products containing BCG vaccine for cancer are classified in L1X9; those for general immunostimulation are classified here. Products containing BCG vaccine for active immunisation against tuberculosis are classified in J7D6.</p> <p>Products containing elapegamase or pegademase for severe combined immunodeficiency disease (SCID) associated with a deficiency of adenosine deaminase are classified here.</p>	r2021
L3B	INTERFERONS	r2024
	<p>Products containing interferons (with or without ribavirin) for multiple indications are classified in L3B. Products containing interferons (with or without ribavirin) for hepatitis only are classified in J5D1. Products containing interferons, eg ropeginterferon alfa 2b, for cancer only are classified in L1X9.</p>	
L3B1	Interferons, alpha	I1994
L3B2	Interferons, beta	R2017
	<p>Products containing beta interferons and indicated for multiple sclerosis only are classified in N7A. Products containing beta interferons and indicated for both multiple sclerosis and other conditions are classified here.</p>	
L3B3	Interferons, gamma	I1994
L3B9	Interferons, non-specified	I1994

L4	IMMUNOSUPPRESSANTS	R2010
L4A	Out of use; can be reused from 2013.	D2010
L4B	ANTI-TNF PRODUCTS Products containing anti-TNF substances are classified here, eg adalimumab, afelimomab, certolizumab pegol, etanercept, golimumab, infliximab. These products can be indicated for multiple conditions, eg rheumatoid arthritis, Crohn's disease, psoriasis. Products containing apremilast for psoriatic conditions only are classified in D5B. Products containing apremilast for multiple conditions are classified in L4X.	r2020
L4C	INTERLEUKIN INHIBITORS Includes products containing interleukin inhibitors, eg basiliximab, canakinumab, daclizumab, riloncept. Includes interleukin inhibitors indicated for the treatment of rejection in organ transplants and for auto-inflammatory diseases such as CAPS (cryopyrin-associated periodic syndromes). Products containing tocilizumab or anakinra and indicated for arthritic conditions are classified in M1C. Products containing tocilizumab or anakinra and indicated for arthritic and also other conditions are classified in M1C. Products containing brodalumab, ixekizumab, secukinumab or ustekinumab and indicated for skin conditions such as psoriasis and also other non-skin conditions, eg rheumatoid arthritis, are classified here. Psoriatic arthritis is defined as a skin condition. Products containing daclizumab and indicated for use in kidney transplantation are classified here. Products containing daclizumab and indicated for multiple sclerosis and other conditions are classified in N7A. Products containing interleukin inhibitors for asthma only are classified in R3M. Products containing interleukin inhibitors for asthma and any of the following conditions, EGPA (eosinophilic granulomatosis with polyangiitis), chronic rhinosinusitis with nasal polyposis, nasal polyps, hypereosinophilic syndrome are classified in R3M. Products containing dupilumab for atopic dermatitis are classified in D5X. Products containing dupilumab for both atopic dermatitis and asthma are classified here. Products containing bimekizumab for psoriatic skin conditions only are classified in D5B. Products containing bimekizumab for both skin conditions and non-skin conditions, eg axial spondyloarthritis, ankylosing spondylitis etc, are classified here. Products containing levilimab for use in COVID-19 are classified here.	r2025

L4D	<p>JAK INHIBITORS</p> <p>Includes products containing JAK inhibitors, eg baricitinib, filgotinib, tofacitinib, upadacitinib, etc. These products are indicated for multiple conditions, eg rheumatoid arthritis, ankylosing spondylitis, atopic dermatitis, ulcerative colitis, etc.</p> <p>Products containing JAK inhibitors primarily for cancer are classified in L1H7.</p> <p>Products containing JAK inhibitors are classified in A7 if only for gastro-intestinal conditions, in D5 if only for skin conditions (eg topical forms of ruxolitinib for atopic dermatitis), and in M1 if only for musculoskeletal conditions.</p>	I2024
L4X	<p>OTHER IMMUNOSUPPRESSANTS</p> <p>Immunosuppressants used in the treatment of rejection in organ transplants are classified here, or in L4C if they contain interleukin inhibitors.</p> <p>Includes eg azathioprine, cyclosporin, muromonab-cd3, mycophenolate mofetil, tacrolimus – unless classified elsewhere because of a specific indication or formulation. For example, ophthalmic cyclosporin for dry eye is classified in S1K9 and dermatological tacrolimus is classified in D5X. Products containing antilymphocyte or antithymocyte immunoglobulins are classified here.</p> <p>Products for multiple sclerosis are classified in N7A. Products containing natalizumab and indicated for multiple sclerosis and other conditions are classified in N7A.</p> <p>Products containing apremilast for psoriatic skin conditions only, are classified in D5B. Psoriatic arthritis is defined as a skin condition. Products containing apremilast for multiple conditions are classified here.</p> <p>Products containing lenalidomide, pomalidomide or thalidomide for multiple myeloma and other cancers are classified in L1K. Products containing thalidomide for both cancer and erythema nodosum leprosum (ENL) are classified in L1K. Products containing thalidomide for erythema nodosum leprosum only are classified here.</p> <p>Products containing leflunomide for multiple conditions are classified here. Products containing leflunomide for rheumatoid arthritis only are classified in M1C.</p> <p>Products containing complement inhibitors: for paroxysmal nocturnal haemoglobinuria (PNH) only are classified in B6X; for kidney conditions only, eg IgA nephropathy, are classified in G4X; for multiple conditions are classified here.</p> <p>Products containing efgartigimod alfa for both myasthenia gravis and immune thrombocytopenia, or both myasthenia gravis and chronic inflammatory demyelinating polyneuropathy (CIDP) are classified here. Products containing efgartigimod alfa for myasthenia gravis only are classified in M5X.</p> <p>Products containing pozelimab for complement hyperactivation, angiopathic</p>	r2025

thrombosis, and protein-losing enteropathy (CHAPLE) disease are classified here.

Products containing vilobelimab for use in COVID-19 are classified here.

Corticosteroids are not classified here.

M5X	<p>ALL OTHER MUSCULOSKELETAL PRODUCTS</p> <p>Includes all other products for disorders of the musculoskeletal system not classified elsewhere. Includes musculoskeletal products containing substances such as cartilage extract, chondroitin, etc. Products containing chondroitin and glucosamine alone or in combination with other substances are classified here. Combinations of glucosamine with nonsteroidal anti-inflammatories are classified in M1A2. Topical glucosamine and chondroitin products are classified in M2A.</p> <p>Includes hydroquinine indicated for restless leg syndrome.</p> <p>Includes herbal products used for musculoskeletal pain.</p> <p>Products containing burosumab for X-linked hypophosphataemia are classified here.</p> <p>Products containing mexiletine for non-dystrophic myotonic disorders are classified here; products containing mexiletine for cardiac arrhythmias are classified in C1B .</p> <p>Products containing diclofenamide for primary periodic paralysis are classified here. Products containing diclofenamide for glaucoma are classified in S1E1. Products containing diclofenamide for diuretic use are classified in C3A9.</p> <p>Products containing vamorolone for Duchenne muscular dystrophy (DMD) are classified here.</p> <p>Products containing amifampridine for Lambert-Eaton myasthenic syndrome are classified here.</p> <p>Products containing nusinersen, onasemnogene abeparvovec or risdiplam for spinal muscle atrophy (SMA) are classified here.</p> <p>Products containing efgartigimod alfa, rozanolixizumab, or zilucoplan for myasthenia gravis only are classified here. Products containing efgartigimod alfa for both myasthenia gravis and immune thrombocytopenia, or both myasthenia gravis and chronic demyelinating immune polyneuropathy (CIDP) are classified in L4X.</p>	r2025
------------	--	-------

N2	<p>ANALGESICS</p> <p>Only includes general purpose analgesics with multiple indications and uses. Thus products specifically used for rheumatic disorders are classified in group M, analgesic cold preparations are classified in R5, products specifically for dysmenorrhoea are classified in G2X.</p>	R2003
N2A	<p>NARCOTICS</p> <p>Includes all analgesics classified as narcotics in accordance with the legal definition of narcotic analgesics in each country.</p>	R1993
N2B	<p>NON-NARCOTICS AND ANTI-PYRETICS</p> <p>Includes systemic products for non-specific analgesia except those classified in N2A (narcotics), N2C (specific anti-migraine preparations), R5A (analgesic/antihistamine cold preparations) and G2X1 (specific dysmenorrhoea preparations).</p> <p>Topical products for analgesia are classified in M2A. Products containing acetylsalicylic acid only are classified in N2B, not M1A. Products containing low-dose oral solid acetylsalicylic acid (162mg and below) are classified in B1C1 (platelet aggregation inhibition).</p> <p>Products containing non-steroidal anti-inflammatories and for both musculoskeletal conditions and analgesia are classified in M1A.</p> <p>Alka-Seltzer, when it contains an analgesic, is classified in N2B. Otherwise, it is classified in A2A1.</p> <p>Products containing muscle relaxants in combination with analgesics are classified in M3.</p> <p>4th level used in Austria, Finland, Hungary, Germany, South Africa, Sweden and Switzerland only.</p>	r2025
N2B1	<p>Prescription-bound non-narcotics and anti-pyretics</p>	
N2B2	<p>Non-prescription-bound non-narcotics and anti-pyretics</p>	
N2C	<p>ANTI-MIGRAINE PREPARATIONS</p>	
N2C1	<p>Anti-migraine selective serotonin agonists</p> <p>These are selective 5HT1 receptor agonists eg almotriptan, eletriptan, frovatriptan, lasmiditan, naratriptan, rizatriptan, sumatriptan, zolmitriptan. Includes triptans and ditans.</p>	r2023

N2C2	<p>Anti-migraine CGRP antagonists</p> <p>Includes products containing CGRP (calcitonin gene-related peptide) antagonists, for example, atogepant, eptinezumab, erenumab, fremanezumab, galcanezumab, rimegepant, ubrogepant, etc.</p>	r2023
N2C9	<p>All other anti-migraine preparations</p> <p>Includes products containing indoramin alone if indicated for migraine.</p>	r2015
N2D	<p>GABAPENTINOID PRODUCTS</p> <p>Includes products containing gabapentinoids, eg crisugabalin, gabapentin, gabapentin enacarbil, mirogabalin, pregabalin, etc. Gabapentinoids for diabetic neuropathy, epilepsy, generalised anxiety disorder, neuropathic pain, restless leg syndrome etc are classified here.</p> <p>Combinations of gabapentinoids with other substances are classified here.</p>	I2025

N3	ANTI-EPILEPTICS	
N3A	ANTI-EPILEPTICS Also includes products for non-epileptic convulsions, eg in pregnancy. Products containing clonazepam are classified here. Products containing gabapentinoids, eg gabapentin, pregabalin, etc, for epilepsy only, and for epilepsy and also other conditions are classified in N2D.	r2025

N4	ANTI-PARKINSON DRUGS	
N4A	ANTI-PARKINSON DRUGS Products containing bromocriptine: for Parkinson's disease only are classified here: for diabetes mellitus only are classified in A10X9: for multiple conditions are classified in G2D: for acromegaly only are classified in H1C2. In Japan, all bromocriptine products are classified here. Products containing ropinirole or similar substances for restless leg syndrome are classified here.	r2025

N7	OTHER CNS DRUGS	R1996
N7A	MULTIPLE SCLEROSIS PRODUCTS	r2025
	<p>Products containing alemtuzumab, dimethyl fumarate, fingolimod, glatiramer acetate, laquinimod, teriflunomide, etc, and indicated for multiple sclerosis only, are classified here.</p>	
	<p>Products containing daclizumab, divozilimab, natalizumab, etc, and indicated for multiple sclerosis and also for other conditions are classified here.</p>	
	<p>Products containing alemtuzumab and indicated for cancer only, are classified in L1G9.</p>	
	<p>Products containing daclizumab for use in kidney transplantation only are classified in L4C.</p>	
	<p>Products containing beta interferons and indicated for multiple sclerosis only are classified here. Products containing beta interferons and indicated for both multiple sclerosis and other conditions are classified in L3B2.</p>	
	<p>Products containing mitoxantrone and indicated for both cancer and multiple sclerosis are classified in L1D.</p>	
	<p>Products containing fampridine for improvement in walking in multiple sclerosis are classified in N7X.</p>	
	<p>Products containing ofatumumab for cancer are classified in L1G1.</p>	
	<p>Products containing sphingosine-1-phosphate (S1P) receptor modulators, eg etrasimod, ozanimod etc, for multiple sclerosis and also other conditions, eg inflammatory bowel disease etc, are classified here. Products containing S1P receptor modulators and indicated for inflammatory bowel disease only are classified in A7E9.</p>	
	<p>Products containing other substances, eg corticosteroids, immunosuppressants such as azathioprine, that have multiple uses, are classified elsewhere.</p>	
N7B	ANTISMOKING PRODUCTS	
	<p>Includes products used to stop smoking.</p>	
N7C	ANTIVERTIGO PRODUCTS	I1996
	<p>Includes betahistine, cinnarizine and flunarizine when indicated for vertigo and Meniere's disease.</p>	

N7D	ANTI-ALZHEIMER PRODUCTS	I1998
N7D1	Anti-Alzheimer products, cholinesterase inhibitors Includes eg donepezil, galantamine, rivastigmine and tacrine.	R2003
N7D9	All other anti-Alzheimer products Includes all other products specifically used for Alzheimer's disease.	I1998
N7E	DRUGS USED IN ALCOHOL DEPENDENCE Includes acamprosate, calcium carbimide, disulfiram. Naltrexone when used in alcohol dependence is classified here.	R2002
N7F	DRUGS USED IN OPIOID DEPENDENCE Includes naltrexone, except when used in alcohol dependence (use N7E).	R2002
N7X	ALL OTHER CNS DRUGS Includes parasympathetic agents. Benzodiazepine antagonists such as flumazenil are classified here. Atomoxetine is included in this class. Products containing gabapentinoids, eg. crisugabalin, gabapentin, gabapentin enacarbil, mirogabalin, pregabalin, etc, plain or in combination with other substances, are classified in N2D. Products containing pilocarpine and indicated for both dry mouth and dry eye are classified here. Products indicated for multiple sclerosis are classified in N7A. Products containing fampridine for improvement in walking in multiple sclerosis are classified here. Products indicated for amyotrophic lateral sclerosis (ALS) are classified here. Products containing tafamidis for transthyretin amyloid polyneuropathy (TAP) only are classified here. Products containing tafamidis for transthyretin amyloid cardiomyopathy (TAC) only are classified in C1X. Products containing tafamidis for both TAP and TAC are classified here. Products containing inebilizumab or satralizumab for neuromyelitis optica spectrum disorder (NMOSD) are classified here. Products containing naloxone for reversal of CNS depression in opioid overdose or intoxication are classified here. Products containing eladocagene exuparvovec for the treatment of human aromatic L-amino acid decarboxylase (AADC) are classified here.	r2025

R7	OTHER RESPIRATORY SYSTEM PRODUCTS	
R7A	RESPIRATORY STIMULANTS Includes centrally acting respiratory stimulants such as lobeline, ethamivan, crotetiamide, croptopamide, nikethamide and doxapram (plain only). Also includes products specifically indicated for primary apnoea in premature newborn babies.	R2006
R7B	CYSTIC FIBROSIS PRODUCTS Products containing dornase alfa for cystic fibrosis are classified in R5C.	I2021
R7B1	Cystic fibrosis transmembrane regulator (CFTR) modulators Includes products containing eg elexacaftor, ivacaftor, lumacaftor, tezacaftor, etc for cystic fibrosis.	I2021
R7C	LUNG SURFACTANTS Includes substances such as colfoscaril palmitate used in neonatal respiratory distress syndrome.	I1996
R7D	IDIOPATHIC PULMONARY FIBROSIS PRODUCTS Includes products containing eg pirfenidone, nintedanib, etc for idiopathic pulmonary fibrosis. Products containing nintedanib for idiopathic pulmonary fibrosis only are classified here. Products containing nintedanib for cancer only are classified in L1H9. Products containing nintedanib for both cancer and idiopathic pulmonary fibrosis are classified here.	I2021
R7X	ALL OTHER RESPIRATORY SYSTEM PRODUCTS Products containing inhaled sargramostim for autoimmune pulmonary alveolar proteinosis (aPAP) are classified in R7X.	r2025

S	SENSORY ORGANS	
S1	OPHTHALMOLOGICALS	
S1A	OPHTHALMOLOGICAL ANTI-INFECTIVES	r2025
	Includes plain anti-infectives: antibacterials (eg sulphonamides), antifungals, and antiparasitics (eg lotilaner). Also includes all anti-infective combinations with the exception of corticosteroid/anti-infective combinations (S1C).	
	Excluded are antiseptics (S1G6) and antivirals (S1D).	
S1B	OPHTHALMOLOGICAL CORTICOSTEROIDS	
	Includes plain corticosteroids and all corticosteroid combinations, with the exception of corticosteroid/anti-infective combinations (S1C).	
S1C	OPHTHALMOLOGICAL ANTI-INFLAMMATORY/ANTI-INFECTIVE COMBINATIONS	R2001
S1C1	Ophthalmological corticosteroid and anti-infective combinations	I2001
S1C2	Ophthalmological NSAIDS and anti-infective combinations	I2001
S1C9	Other ophthalmological anti-inflammatory and anti-infective combinations	I2001
S1D	OPHTHALMOLOGICAL ANTIVIRAL AGENTS	r2008
	Includes aciclovir, iododesoxycytidine, idoxuridine, 5-ethyl-2' deoxyuridine, trifluridine, tromantadine, vidarabine. Systemic forms of products for cytomegalovirus retinitis are classified in J5B3.	
S1E	MIOTICS AND ANTIGLAUCOMA PREPARATIONS	
S1E1	Miotics and antiglaucoma preparations, systemic	r2021
	Includes carboanhydrase inhibitors (acetazolamide, diclofenamide and methazolamide), only when they are specifically promoted and used for the treatment of glaucoma (see also C3A9). Products containing diclofenamide for primary periodic paralysis are classified in M5X and for diuretic use are classified in C3A9.	
S1E2	Miotics and antiglaucoma preparations, topical	R2007
	Includes parasympathomimetics (acelidine, acetylcholine, clonidine, pilocarpine); anticholinesterases or cholinesterase inhibitors (carbachol, demecarium bromide, distigmine, ecothiopate iodide, isofluorophate (DFP), neostigmine, paraoxon, physostigmine); sympathicolitics (guanethidine); beta-blockers (bupranolol, timolol); sympathomimetics (adrenaline/epinephrine); prostaglandin analogues; carbo-anhydrase inhibitors.	

S1X	<p data-bbox="316 170 831 203">OTHER OPHTHALMOLOGICALS</p> <p data-bbox="316 248 1394 389">Includes preparations which improve regeneration (iodine); preparations which improve retinal blood flow (heparin, tolazoline); preparations which improve adaptation and all other ophthalmological preparations not mentioned in S1A-S1T. Products used for diabetic retinopathy are classified here.</p>	r2016
S1X1	<p data-bbox="316 427 791 461">Other ophthalmologicals, systemic</p>	I1993
S1X2	<p data-bbox="316 506 767 539">Other ophthalmologicals, topical</p> <p data-bbox="316 577 1394 645">Products containing topical sirolimus for chronic non-infectious uveitis are classified here.</p> <p data-bbox="316 689 1394 757">Products for geographic atrophy, such as avacincaptad pegol and ophthalmic pegcetacoplan, are classified in S1X2.</p>	r2025

V3G2	<p>Hyperphosphataemia products</p> <p>Includes products used specifically for hyperphosphataemia, eg those containing bixalomer, calcium acetate, calcium acetate in combination with magnesium carbonate, calcium carbonate, colestilan, ferric citrate, lanthanum carbonate, sevelamer, sucroferric oxyhydroxide, etc.</p> <p>Products containing calcium and indicated in both hyperphosphataemia and calcium deficiency are classified in V3G2.</p>	I2016
V3H	<p>ANTI-INFLAMMATORY ENZYMES</p> <p>This group includes all enzyme preparations which are indicated to treat inflammatory conditions. Includes enzyme preparations for respiratory conditions. Excluded are enzyme preparations used in digestive conditions which are classified in A9A. Also excluded are specific cholagogues - classified in A5A, enzymatic topical wound treatments - classified in D3A, enzymes for ophthalmic use - classified in S1S9.</p>	R2007
V3X	<p>ALL OTHER THERAPEUTIC PRODUCTS</p> <p>Includes products with multiple anatomical effects, not readily classifiable in any single group. Large packs of chemicals (bulk packs) which are intended for preparation of formulations in the pharmacy/laboratory are classified here. Kelp products are classified here. Includes medical oxygen cylinders.</p> <p>Products containing omega-3 fatty acids for the reduction of triglycerides and/or the prevention and treatment of arteriosclerosis are classified in C10B. Products containing omega-3 fatty acids for other conditions (including supplementation in pregnancy and breastfeeding) or for multiple uses are classified here.</p> <p>Products containing lonafarnib for Hutchinson-Gilford progeria syndrome or progeroid laminopathies are classified here.</p> <p>Products containing antioxidants, eg glutathione, ubidecarenone etc, for general health and/or wellbeing are classified here.</p> <p>4th level used only in Germany and Hungary.</p>	r2025
V3X1	<p>Umstimmungsmittel preparations of herbal origin</p> <p>Products which are said to intensify the body's defence against infection.</p>	I2006
V3X4	<p>Cure-all preparations</p> <p>These products have a broad spectrum of indications for internal and external use. Includes products containing a mixture of homeopathic together with allopathic or herbal ingredients. These products can have several indications.</p>	I2006

